Hemo Organic [HEMORGANIC] vs Sequent Scientific [SEQUENT] Detailed Stock Comparison
Hemo Organic
BSE
Loading...
Sequent Scientific
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Hemo Organic wins in 9 metrics, Sequent Scientific wins in 9 metrics, with 0 ties. Both stocks appear equally matched on key metrics.
View Metrics Details
Vital Metrics Comparison
| Metric | Hemo Organic | Sequent Scientific | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 44.87 | 157.76 | Hemo Organic |
| Price-to-Book Ratio | -21.72 | 6.44 | Hemo Organic |
| Debt-to-Equity Ratio | -9.77 | 62.47 | Hemo Organic |
| PEG Ratio | 0.02 | 1.32 | Hemo Organic |
| EV/EBITDA | 184.53 | 30.37 | Sequent Scientific |
| Profit Margin (TTM) | 3.28% | 1.85% | Hemo Organic |
| Operating Margin (TTM) | -6,026.32% | 7.56% | Sequent Scientific |
| EBITDA Margin (TTM) | N/A | 7.56% | N/A |
| Return on Equity | -108.18% | 2.84% | Sequent Scientific |
| Return on Assets (TTM) | 3.29% | 1.37% | Hemo Organic |
| Free Cash Flow (TTM) | $-3.62M | $442.73M | Sequent Scientific |
| 1-Year Return | -20.17% | 15.68% | Sequent Scientific |
| Price-to-Sales Ratio (TTM) | 1.44 | 2.84 | Hemo Organic |
| Enterprise Value | $47.24M | $50.45B | Sequent Scientific |
| EV/Revenue Ratio | 1.90 | 3.15 | Hemo Organic |
| Gross Profit Margin (TTM) | 26.32% | 46.86% | Sequent Scientific |
| Revenue per Share (TTM) | $7 | $64 | Sequent Scientific |
| Earnings per Share (Diluted) | $0.23 | $1.15 | Sequent Scientific |
| Beta (Stock Volatility) | -0.06 | 0.91 | Hemo Organic |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Hemo Organic vs Sequent Scientific Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Hemo Organic | -9.83% | -2.42% | -4.34% | -11.05% | -0.75% | -18.99% |
| Sequent Scientific | 1.03% | 9.93% | 13.87% | 6.68% | 38.79% | 8.66% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Hemo Organic | -20.17% | -59.74% | -20.17% | -56.11% | -92.59% | 39.04% |
| Sequent Scientific | 15.68% | 88.39% | 37.14% | 36.09% | 36.09% | 36.09% |
News Based Sentiment: Hemo Organic vs Sequent Scientific
Hemo Organic
News sentiment data is not available for Hemo Organic at this time.
Sequent Scientific
News based Sentiment: POSITIVE
September was a strong month for Sequent Scientific, driven by impressive Q1 FY26 earnings and increased institutional investment. While a director resigned, the overall narrative is positive, suggesting continued growth and investor confidence. The analyst 'Buy' rating and rising share price further support a favorable outlook.
Performance & Financial Health Analysis: Hemo Organic vs Sequent Scientific
| Metric | HEMORGANIC | SEQUENT |
|---|---|---|
| Market Information | ||
| Market Cap | ₹33.48M | ₹46.87B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 3,947 | 479,608 |
| 90 Day Avg. Volume | 2,540 | 496,709 |
| Last Close | ₹9.26 | ₹200.64 |
| 52 Week Range | ₹8.05 - ₹13.70 | ₹117.35 - ₹240.70 |
| % from 52W High | -32.41% | -16.64% |
| All-Time High | ₹2,386.00 (Apr 21, 2008) | ₹336.50 (Jun 28, 2021) |
| % from All-Time High | -99.61% | -40.37% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -1.00% | 0.13% |
| Quarterly Earnings Growth | N/A | 1.20% |
| Financial Health | ||
| Profit Margin (TTM) | 0.03% | 0.02% |
| Operating Margin (TTM) | -60.26% | 0.08% |
| Return on Equity (TTM) | -1.08% | 0.03% |
| Debt to Equity (MRQ) | -9.77 | 62.47 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹-0.44 | ₹28.19 |
| Cash per Share (MRQ) | ₹0.03 | ₹2.52 |
| Operating Cash Flow (TTM) | ₹-38,918,000 | ₹360.47M |
| Levered Free Cash Flow (TTM) | ₹1.64M | ₹218.78M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | ₹0.00 |
Valuation & Enterprise Metrics Analysis: Hemo Organic vs Sequent Scientific
| Metric | HEMORGANIC | SEQUENT |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 44.87 | 157.76 |
| Forward P/E | N/A | 35.92 |
| PEG Ratio | 0.02 | 1.32 |
| Price to Sales (TTM) | 1.44 | 2.84 |
| Price to Book (MRQ) | -21.72 | 6.44 |
| Market Capitalization | ||
| Market Capitalization | ₹33.48M | ₹46.87B |
| Enterprise Value | ₹47.24M | ₹50.45B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.90 | 3.15 |
| Enterprise to EBITDA | 184.53 | 30.37 |
| Risk & Other Metrics | ||
| Beta | -0.06 | 0.91 |
| Book Value per Share (MRQ) | ₹-0.44 | ₹28.19 |
Financial Statements Comparison: Hemo Organic vs Sequent Scientific
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | HEMORGANIC | SEQUENT |
|---|---|---|
| Revenue/Sales | ₹19,000 | ₹4.41B |
| Cost of Goods Sold | ₹14,000 | ₹2.35B |
| Gross Profit | ₹5,000 | ₹2.07B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹-1.15M | ₹333.50M |
| EBITDA | ₹-1.14M | ₹505.30M |
| Pre-Tax Income | ₹-1.15M | ₹255.20M |
| Income Tax | ₹-288,000 | ₹79.50M |
| Net Income (Profit) | ₹-857,000 | ₹175.70M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | HEMORGANIC | SEQUENT |
|---|---|---|
| Cash & Equivalents | ₹87,000 | ₹626.60M |
| Total Current Assets | ₹46.94M | ₹8.74B |
| Total Current Liabilities | ₹36.47M | ₹5.05B |
| Long-Term Debt | ₹14.80M | ₹3.00B |
| Total Shareholders Equity | ₹-1.52M | ₹7.70B |
| Retained Earnings | N/A | ₹1.25B |
| Property, Plant & Equipment | ₹20,000 | ₹2.84B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | HEMORGANIC | SEQUENT |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | HEMORGANIC | SEQUENT |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 3,947 | 479,608 |
| Average Daily Volume (90 Day) | 2,540 | 496,709 |
| Shares Outstanding | 3.47M | 249.89M |
| Float Shares | 1.92M | 117.77M |
| % Held by Insiders | 0.42% | 0.53% |
| % Held by Institutions | 0.00% | 0.13% |
Dividend Analysis & Yield Comparison: Hemo Organic vs Sequent Scientific
| Metric | HEMORGANIC | SEQUENT |
|---|---|---|
| Last 12-Month Dividend | N/A | ₹0.00 |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | ₹0.00 |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | ₹0.00 |
| Ex-Dividend Date | N/A | N/A |